Clinical Trial Update: Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating talacotuzumab or daratumumab in transfusion-dependent myelodysplastic syndrome patients relapsed or refractory to erythropoiesis-stim…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Daratumumab (daratumumab)
• Talacotuzumab (talacotuzumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED | Results posted: 2020-03-13